Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS111 in Advanced NSCLC With EGFR Mutations
NCT06940401Phase 2Active, not recruiting
- Sponsor
- Suzhou Junjing BioSciences
- Start
- Apr 2025
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of js111 in non-small cell lung cancer (NSCLC), sponsored by Suzhou Junjing BioSciences. Started Apr 2025; status: active, not recruiting.
02
Drugs
js111
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06940401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06940401.